-=Audentes Therapeutics (BOLD) reported earnings on Wed 9 May 2018 (a/h)

Audentes Therapeutics beats by $0.07 

• Reports Q1 (Mar) loss of $0.74 per share, $0.07 better than the Capital IQ Consensus of ($0.81).
• Plan to report additional interim data during an oral presentation at ASGCT on May 16, 2018. Presentation to include up to 24-week data for the first four subjects enrolled and up to 4-week data in the cohort 1 expansion patients.